CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 55 enrolled
Drug / intervention
Adalimumabbiological
Likely dose
Adalimumab pre-filled syringe administered by subcutaneous injection (standard dosing)AI-extracted
Key inclusion· 5
  • ✓Confirmed diagnosis of rheumatoid arthritis by ACR 1987 and/or ACR/EULAR 2010 criteria
  • ✓Moderate to severe RA with DAS28 ESR or DAS28 CRP >3.2
  • ✓Biologically treatment naïve at baseline with adalimumab initiation
  • ✓Clinical data available for 12 weeks prior to baseline
Key exclusion· 4
  • ✕Pregnant, breastfeeding, or planning pregnancy within 24 weeks
  • ✕Participation in any RA-related clinical trial within 24 weeks prior to baseline or at enrollment
  • ✕Clinician concern about inability to accurately report quality of life or prior resource utilization
  • ✕Clinician concern about inability to adhere to adalimumab therapy over 24 weeks

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02668640
NCT02668640N/ACompleted
CompareCT.gov

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China (ROCKI Study)

AbbVie·observational·Posted Jan 29, 2016·Updated Sep 13, 2019

In Brief

An observational study evaluating Adalimumab for Rheumatoid Arthritis. Completed, enrolled 55 participants.

Detailed Summary

The objective of this study was to assess the effectiveness of adalimumab on health and disability outcomes in participants with rheumatoid arthritis (RA) in China.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 29, 2016
Enrollment StartMay 1, 2016
Primary CompletionJun 12, 2018
Study CompletionAug 13, 2018
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.4 years ago

Interventions

Adalimumabbiological

Pre-filled syringe, administered by subcutaneous injection